期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CAG方案治疗中高危骨髓增生异常综合征的疗效分析 被引量：3

原文传递
导出
摘要 目的观察CAG方案治疗中高危骨髓增生异常综合征（MDS）的临床疗效和不良反应。方法CAG方案治疗MDS患者21例，其中中危．I3例，中危．Ⅱ13例，高危5例，治疗1个疗程评估疗效，有效者继续治疗1～2个疗程，无效则退出观察。结果21例患者总有效率为85．7％（18／21），其中完全缓解8例，部分缓解7例，血液学进步3例，无效3例。19例患者出现轻度（I～Ⅱ度）骨髓抑制，2例出现较重骨髓抑制，其中1例抑制严重，死于严重粒细胞缺乏合并菌血症。结论CAG方案治疗中高危MDS安全有效，但长期疗效有待进一步观察。
作者 余海 李敏 林永慧 朱鹏 余和平
机构地区 上海市静安区中心医院血液科
出处 《中国医师进修杂志》 2014年第1期40-41,共2页 Chinese Journal of Postgraduates of Medicine
关键词 骨髓增生异常综合征 临床方案
分类号 R551.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献10

二级参考文献27

  • 1ChesonBD,BennettJM,KopeckyKJ,周学慧,肖志坚.国际工作组关于急性髓系白血病治疗试验的诊断、疗效标准的标准化、治疗结局和报告标准的修订建议[J].白血病．淋巴瘤,2004,13(4):246-250. 被引量：31
  • 2Greenberg P, Cox C, LeBeau M M, et al. Znternational scoring system for evaluating prognosis in myelodysplastic syndroms[J]. Blood,1997, 89(6) :2079 -2088.
  • 3Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-close cytosine arabino- side and aclarubicin for previously treated acute myelogenous leukemia: a pilot study[J]. Leukemia, 1995,9 (1): 10-14.
  • 4Saito K, Nakamaura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubcin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with replapsed or primary resistant acute myelogenous leukemia and previously untreated elderly patients with AML, secondary AML, and refractory anima with excess blastsin transformation[J]. . Int J Hematol,2000 ,71(3):238-244.
  • 5Bai A, Kojima H, Hori M, et,al. Priming with G-CSF effectively enhances low dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells[J]. Exp Hematol , 1999,27 (2) : 259-265.
  • 6Nakamura Y, Arai Y, Gunji H, et al. WT1 gene expression in patients with acute myelogenous leukemia or high risk myelodys- plastic syndrome successfully treated with CAG regimen[J]. Rinsho Ketsueki,2002,43(10) :960-962.
  • 7Harouseau J L,WuD P.The use of GM-CSF and G - CSF in the treatment of acute leukemia[J].Leuk Lymphoma,1995,18:405-412.
  • 8Amuguleng B,Hiroshi K,Mitsuo H,et al.Priming with G- CSF effectively enhances low-dose Ara-c induced in vivo apoptosis in myeloid leukemia cells [J].Exp Hematol,1999,27:259-265.
  • 9Yamada K,Fnrusawa S,Saito K,et al.Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinosid and aclarubicin for previously treated acute myelogenous leukemia:a pilod study [J].Leukemia,1995,9:10-14.
  • 10Saito K,Nakamura Y,Aoyagi M,et al.Lowdose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor(CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia(AML) and previously untreated elderly patients with AML,secondary AML,and refractory anemia with excess blasts in transformation[J].Iht J Hematol,2000,71:238-244.

共引文献53

同被引文献37

  • 1Yang L, Mailloux A, Rollison DE, et al. Naive T -cells in myelodys- plastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency[ J]. Leukemia, 2013,27 (4) :897 - 906.
  • 2Attar EC, Amrein PC, Fraser JW, et al. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelo- dysplastic syndromes (MDS) and acute myeloid leukemia (AML) [ J]. Leuk Res, 2013,37(9) :1016 - 1020.
  • 3Santini V, Alessandrino PE, Angelucci E, et al. Clinical management of myelodysplastic syndromes : update of SIE, SIES, GITMO practice guidelines [J]. Leuk Res, 2010,34(12) :1576 - 1588.
  • 4Alien SL, Kolitz JE, Lundberg AS, et al. Phase I trims of amonafide as monotherapy and in combination with eytarabine in patients with poor - risk acute myeloid leukemia [ J]. Leuk Res, 2010,34(4) :487 -491.
  • 5Cheson BD, Greenberg PL, Bennett JM, el al. Clinical pplication and proposal for modification of the International Working Group ( IWG ) re- sponse criteria in myelodysplasia [ J ]. Blood, 2006,108 (2) :419 - 425.
  • 6Yoshimi A, Strahm B, Baumann I, et al. Hematopoietic stem cell transplantation in children and young adults with secondary myelodys- plastic syndrome and acute myelogenous leukemia after aplastic anemia [J]. Biol Blood Marrow Transplant, 2014,20(3) :425 -429.
  • 7Potter VT, Krishnamurthy P, Barber LD, et al. Long - term outcomes of alemtuzumab - based reduced - intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelog- enous leukemia secondary to myelodysplastic syndrome [ J ]. Biol Blood Marrow Transplant, 2014,20 ( 1 ) : 111 - 117.
  • 8Itzykson R, Th6pot S, Quesnel B, et al, Prognostic factors for response and overall survival in 282 patients with higher - risk myelodysplastic syndromes treated with azacitidine [ J ]. Blood, 2011,117 ( 2 ) : 403 - 411.
  • 9F enaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher - risk myelodysplastic syndromes : azaciti- dine compared With low dose ara - C [ J]. Br J Haematol, 2010, i49 (2) :244 -249.
  • 10刘国珍,王春波,李光耀.沙利度胺抗肿瘤作用机制研究进展及在骨髓增生异常综合征治疗中的应用[J].山东医药,2009,49(11):117-118. 被引量：5

引证文献3

二级引证文献17

中国医师进修杂志
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部